Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Inclusion Criteria: * Age ≥18 years. * Patients with histologically- or cytologically-proven, surgically unresectable, locally advanced pancreatic adenocarcinoma. * If the patient does not have a diagnostic biopsy that is adequate for review at our institution, the patient must agree to a research core biopsy to be performed at Johns Hopkins. * If the patient's available imaging is not adequate for review by our institution, the patient must agree to a repeat imaging to be performed at Johns Hopkins. * ECOG performance status 0 or 1 * Life expectancy greater than 3 months. * Able to swallow pills or capsules. * Patient must have adequate organ function defined by the study-specified laboratory tests. * Patients must be eligible to receive FOLFIRINOX-based chemotherapy. * Patients must be willing to be treated with stereotactic body radiation therapy (SBRT) only at Johns Hopkins Hospital. * Patients must be willing to undergo a core biopsy of the pancreatic cancer. * Patients must be willing to undergo a biopsy of the pancreatic cancer if the patient is not deemed a surgical candidate during the pre-surgical evaluation. * Must use acceptable form of birth control while on study. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Patients cannot have had any prior therapy for the locally advanced pancreatic adenocarcinoma. * Have received any anti-neoplastic biologics, vaccines or hormonal treatment, including investiga…